浙江龍盛(600352.SH)披露2020年員工持股計劃(草案)
格隆匯5月7日丨浙江龍盛(600352.SH)披露2020年員工持股計劃(草案),該員工持股計劃設立時計劃份額合計不超過3.367億份,資金總額不超過6.73億元。參加對象認購員工持股計劃的款項來源於其合法薪酬、自籌資金等合法途徑。
參加本次員工持股計劃的員工總人數為7人,為公司董事(不含獨立董事)、高級管理人員。
員工持股計劃股票來源:公司回購專用賬户回購的公司股票。
該員工持股計劃購買回購股票的價格為董事會審議日(2020年5月7日)前20個交易日公司股票均價的80%,即本員工持股計劃受讓公司回購股票的價格為9.61元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.